Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.

Teh TC, Nguyen NY, Moujalled DM, Segal D, Pomilio G, Rijal S, Jabbour A, Cummins K, Lackovic K, Blombery P, Thompson E, Ekert PG, Lessene G, Glaser SP, Huang DCS, Roberts AW, Guthridge MA, Wei AH.

Leukemia. 2018 Feb;32(2):303-312. doi: 10.1038/leu.2017.243. Epub 2017 Jul 28.

PMID:
28751770
2.

Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics.

Lalaoui N, Hänggi K, Brumatti G, Chau D, Nguyen NN, Vasilikos L, Spilgies LM, Heckmann DA, Ma C, Ghisi M, Salmon JM, Matthews GM, de Valle E, Moujalled DM, Menon MB, Spall SK, Glaser SP, Richmond J, Lock RB, Condon SM, Gugasyan R, Gaestel M, Guthridge M, Johnstone RW, Munoz L, Wei A, Ekert PG, Vaux DL, Wong WW, Silke J.

Cancer Cell. 2016 Sep 12;30(3):499-500. doi: 10.1016/j.ccell.2016.08.009. Epub 2016 Sep 12. No abstract available.

3.

Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.

Bilardi RA, Anstee NS, Glaser SP, Robati M, Vandenberg CJ, Cory S.

Cell Death Dis. 2016 Sep 1;7(9):e2351. doi: 10.1038/cddis.2016.258.

4.

Rapid Inflammation in Mice Lacking Both SOCS1 and SOCS3 in Hematopoietic Cells.

Ushiki T, Huntington ND, Glaser SP, Kiu H, Georgiou A, Zhang JG, Metcalf D, Nicola NA, Roberts AW, Alexander WS.

PLoS One. 2016 Sep 1;11(9):e0162111. doi: 10.1371/journal.pone.0162111. eCollection 2016.

5.

Eliminating Legionella by inhibiting BCL-XL to induce macrophage apoptosis.

Speir M, Lawlor KE, Glaser SP, Abraham G, Chow S, Vogrin A, Schulze KE, Schuelein R, O'Reilly LA, Mason K, Hartland EL, Lithgow T, Strasser A, Lessene G, Huang DC, Vince JE, Naderer T.

Nat Microbiol. 2016 Feb 24;1:15034. doi: 10.1038/nmicrobiol.2015.34.

PMID:
27572165
6.

MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL.

Vikström IB, Slomp A, Carrington EM, Moesbergen LM, Chang C, Kelly GL, Glaser SP, Jansen JH, Leusen JH, Strasser A, Huang DC, Lew AM, Peperzak V, Tarlinton DM.

Cell Death Dis. 2016 Aug 25;7(8):e2345. doi: 10.1038/cddis.2016.237.

7.

Site-specific recombinatorics: in situ cellular barcoding with the Cre Lox system.

Weber TS, Dukes M, Miles DC, Glaser SP, Naik SH, Duffy KR.

BMC Syst Biol. 2016 Jun 30;10(1):43. doi: 10.1186/s12918-016-0290-3.

8.

The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.

Brumatti G, Ma C, Lalaoui N, Nguyen NY, Navarro M, Tanzer MC, Richmond J, Ghisi M, Salmon JM, Silke N, Pomilio G, Glaser SP, de Valle E, Gugasyan R, Gurthridge MA, Condon SM, Johnstone RW, Lock R, Salvesen G, Wei A, Vaux DL, Ekert PG, Silke J.

Sci Transl Med. 2016 May 18;8(339):339ra69. doi: 10.1126/scitranslmed.aad3099. Erratum in: Sci Transl Med. 2017 May 31;9(392):.

PMID:
27194727
9.

BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells.

Xu Z, Sharp PP, Yao Y, Segal D, Ang CH, Khaw SL, Aubrey BJ, Gong J, Kelly GL, Herold MJ, Strasser A, Roberts AW, Alexander WS, Burns CJ, Huang DC, Glaser SP.

Leukemia. 2016 Jul;30(7):1531-41. doi: 10.1038/leu.2016.52. Epub 2016 Mar 8.

PMID:
27055867
10.

Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics.

Lalaoui N, Hänggi K, Brumatti G, Chau D, Nguyen NY, Vasilikos L, Spilgies LM, Heckmann DA, Ma C, Ghisi M, Salmon JM, Matthews GM, de Valle E, Moujalled DM, Menon MB, Spall SK, Glaser SP, Richmond J, Lock RB, Condon SM, Gugasyan R, Gaestel M, Guthridge M, Johnstone RW, Munoz L, Wei A, Ekert PG, Vaux DL, Wong WW, Silke J.

Cancer Cell. 2016 Feb 8;29(2):145-58. doi: 10.1016/j.ccell.2016.01.006. Erratum in: Cancer Cell. 2016 Sep 12;30(3):499-500.

11.

Acute myeloid leukemia requires Hhex to enable PRC2-mediated epigenetic repression of Cdkn2a.

Shields BJ, Jackson JT, Metcalf D, Shi W, Huang Q, Garnham AL, Glaser SP, Beck D, Pimanda JE, Bogue CW, Smyth GK, Alexander WS, McCormack MP.

Genes Dev. 2016 Jan 1;30(1):78-91. doi: 10.1101/gad.268425.115.

12.

Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells.

Sathe P, Delconte RB, Souza-Fonseca-Guimaraes F, Seillet C, Chopin M, Vandenberg CJ, Rankin LC, Mielke LA, Vikstrom I, Kolesnik TB, Nicholson SE, Vivier E, Smyth MJ, Nutt SL, Glaser SP, Strasser A, Belz GT, Carotta S, Huntington ND.

Nat Commun. 2014 Aug 14;5:4539. doi: 10.1038/ncomms5539.

PMID:
25119382
13.

Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.

Khaw SL, Mérino D, Anderson MA, Glaser SP, Bouillet P, Roberts AW, Huang DC.

Leukemia. 2014 Jun;28(6):1207-15. doi: 10.1038/leu.2014.1. Epub 2014 Jan 9.

PMID:
24402163
14.

Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53.

Kelly GL, Grabow S, Glaser SP, Fitzsimmons L, Aubrey BJ, Okamoto T, Valente LJ, Robati M, Tai L, Fairlie WD, Lee EF, Lindstrom MS, Wiman KG, Huang DC, Bouillet P, Rowe M, Rickinson AB, Herold MJ, Strasser A.

Genes Dev. 2014 Jan 1;28(1):58-70. doi: 10.1101/gad.232009.113.

15.

Enhanced stability of Mcl1, a prosurvival Bcl2 relative, blunts stress-induced apoptosis, causes male sterility, and promotes tumorigenesis.

Okamoto T, Coultas L, Metcalf D, van Delft MF, Glaser SP, Takiguchi M, Strasser A, Bouillet P, Adams JM, Huang DC.

Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):261-6. doi: 10.1073/pnas.1321259110. Epub 2013 Dec 20.

16.

HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia.

Brumatti G, Salmanidis M, Kok CH, Bilardi RA, Sandow JJ, Silke N, Mason K, Visser J, Jabbour AM, Glaser SP, Okamoto T, Bouillet P, D'Andrea RJ, Ekert PG.

Oncotarget. 2013 Nov;4(11):1933-47.

17.

Reversible growth factor dependency and autonomy during murine myelomonocytic leukemia induced by oncogenes.

Metcalf D, Glaser SP, Xu Z, Di Rago L, Mifsud S.

Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17029-34. doi: 10.1073/pnas.1317055110. Epub 2013 Sep 30.

18.

Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.

Thomas D, Powell JA, Vergez F, Segal DH, Nguyen NY, Baker A, Teh TC, Barry EF, Sarry JE, Lee EM, Nero TL, Jabbour AM, Pomilio G, Green BD, Manenti S, Glaser SP, Parker MW, Lopez AF, Ekert PG, Lock RB, Huang DC, Nilsson SK, Récher C, Wei AH, Guthridge MA.

Blood. 2013 Aug 1;122(5):738-48. doi: 10.1182/blood-2012-08-447441. Epub 2013 Jun 17.

PMID:
23775716
19.

Mcl-1 is essential for the survival of plasma cells.

Peperzak V, Vikström I, Walker J, Glaser SP, LePage M, Coquery CM, Erickson LD, Fairfax K, Mackay F, Strasser A, Nutt SL, Tarlinton DM.

Nat Immunol. 2013 Mar;14(3):290-7. doi: 10.1038/ni.2527. Epub 2013 Feb 3. Erratum in: Nat Immunol. 2013 Aug;14(8):877.

20.

Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.

Mérino D, Khaw SL, Glaser SP, Anderson DJ, Belmont LD, Wong C, Yue P, Robati M, Phipson B, Fairlie WD, Lee EF, Campbell KJ, Vandenberg CJ, Cory S, Roberts AW, Ludlam MJ, Huang DC, Bouillet P.

Blood. 2012 Jun 14;119(24):5807-16. doi: 10.1182/blood-2011-12-400929. Epub 2012 Apr 26.

21.

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia.

Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, Izon DJ, Zuber J, Rappaport AR, Herold MJ, Alexander WS, Lowe SW, Robb L, Strasser A.

Genes Dev. 2012 Jan 15;26(2):120-5. doi: 10.1101/gad.182980.111.

Supplemental Content

Loading ...
Support Center